The Instant Results Of Preoperative Hepatic Artery Chemoembolization In Hepatocellular Carcinoma Developed On The Background Of Cirrhosis.

M Juraev, O Nematov, A Yusupbekov


Importance: Treatment of hepatocellular carcinoma remains a topical issue of Clinical Oncology. More than 80% of cases hepatocellular carcinoma develops in the presence of liver cirrhosis. These patients are doomed, many clinics they held only symptomatic treatment and life expectancy of patients is not more than 6 months. The main reason for the refusal of surgeons and Chemotherapeutists of treatment is associated cirrhosis.

Purpose: To improve results of surgical treatment of liver cancer developed on cirrhosis

Materials and methods: We analyzed the immediate results of treatment of 12 patients with hepatocellular carcinoma developed on a background of liver cirrhosis. From - the large size of the tumor and associated liver cirrhosis, these patients the first stage of oil produced by hepatic artery chemoembolization of the affected lobe of the liver tumor. After 2 - 3 weeks performed liver resection.

Results: After analyzing the results, we concluded: chemoembolization reduces tumor volume and weight, increases the physiological regeneration of hepatocytes unaffected tumor fraction, improves functional performance of the liver and does not affect the frequency and severity of postoperative complications.


Hepatocellular Carcinoma, Oil Chemoembolization Of The Hepatic Artery, Liver Resection, Liver Cirrhosis.

Full Text:



Vishnevsky VA, Kubyshkin VA, Zhao A., Ikramov RZ Operations on the liver. Guide for surgeons. -M., 2003. -C. 27-29.

Granov DA, Taraz, PG Endovascular intervention in the treatment of malignant liver tumors. Folio. -St., 2002. -288 Sec.

Islambekova ZA Hepatocellular carcinoma and viral hepatitis: a causal connection, the course and approach to treatment: "Candidate. ... Dr. med. Science. , Tashkent, 2009.

AE Kolosov, VA Zhuravlev Liver cancer and the prognosis for patients. - St.: Kirov, 2002. -230 Sec.

Com AV, Roshchin EV Gurtovaya IB Drug treatment of primary and metastatic liver cancer. Monograph. - Moscow: Triada-X, 2002. -C. 21-31.

Patyutko YI Surgical treatment of malignant liver tumors / Surgical treatment of malignant liver tumors. -M., 2005. , P.17-23.

Patyutko YI Epidemiology, molecular biology and prevention of liver cancer / surgical treatment of malignant liver tumors. -M: the practice of medicine, 2005. -312 Sec.

Taraz PG Preoperative embolization of the portal vein for liver tumors, Vestnik surgery. -2001. -T.160. - № 1. , P.117-121.

Sherlock S., Dooley J. Diseases of the liver and biliary tract. Monograph. -2002. -C. 600-620.

Bosch F.X., Ribes J., Diaz M. Primary liver cancer: worldwide incidence and trends / / Gastroenterology. -2004. -V.5. - № 1. -P.5-16.

Fattovich G., Stroffolini T., Zagni I. Hepatocellular carcinoma in cirrhosis: incidence and risk factors / / Gastroenterology. -2004. -V.5. - № 1. -P. S35-50.

Groupe d'Etude et de treatment du Carcinome Hepatocellulare. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma / / N. Engl. J. Med. -1995. -V.332. -P.1256-1261.

Kamangar F., Dores GM, Anderson WF, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world / / J. Clin. Oncol. -2006. -V.24. R.2137-2150.

Lencioni R., Malagari K., Vogl T. et al. A randomized phase II trial of a drug eluting beads in the treatment of HCC by transcatheter arterial chemoembolisation (TACE) / /; Gl. Cancer Symp. 2009; Abst. 116.

Lo C.M., Ngan H., Tso W.K. et al. Randomized controlled trial of transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma. / / J. Hepatol. -2002. -V.35. - № 5. -P.1164-1171.

Montalto G., Cervello M., Giannitrapani L. Epidemiology, risk factors, and natural history of hepatocellular carcinoma / / Ann. N. Y. Acad. Sci. -2002. - № 963. -R.13-20.

Rodriguez-Diaz JL, Rosas-Camargo V., Vega-Vega O. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study / / Clin. Oncol. -2007. -V.19. - № 3. -R.197-203.

Portolani N., Tiberio G., Bonardelli S. Arterial chemoembolisation in hepatocellular carcinoma suitable for resective surgery / / Hep-Gastroenter. -1996. -V.12. - № 43. -R.1566-1574.

Velazquez R.F., Rodriguez M., Navascues C.A. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis / / Hepatology. -2003. -V.37. - № 3. -R.520-527.

Verslype C., Dicato D., De Gramont A. et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10 th World Congress on Gastrointestinal Cancer, Barcelona, 2008. / / Annals of Oncology. -2009. -V.20 (Suppl.7). -P.1-6.



  • There are currently no refbacks.

Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.